CYAD - Celyad Oncology slips 5% after suspending developmemt of CYAD-01 in early-stage THINK trial

Celyad Oncology (CYAD) announces updates from its shRNA-based anti-B cell maturation antigen ((BCMA)) allogeneic CAR T candidate, CYAD-211, and autologous NKG2D receptor-based CAR T candidates, CYAD-01 and CYAD-02. CYAD-211 and IMMUNICY-1 Phase 1 Trial Update:IMMUNICY-1 will evaluate the safety and clinical activity of a single infusion of CYAD-211 following preconditioning chemotherapy cyclophosphamide and fludarabine in patients with relapsed/refractory multiple myeloma (r/r MM). CYAD-211 demonstrated robust anti-tumor activity in vitro and in vivo concurrent with lack of alloreactivity in preclinical MM models.No demonstrable evidence of GvHD was observed confirming efficient inhibition of alloreactivity. Proof-of-principle data from the initial dose cohorts and clinical activity data from the full dose-escalation trial are expected during H1 and H2 2021, respectively. CYAD-01 and THINK Phase 1 Trial Update: CYAD-01 was evaluated for the treatment of patients with r/r acute myeloid leukemia ((AML)) and myelodysplastic syndrome ((MDS)) in the Phase 1 THINK trial.Overall, 8 of the

For further details see:

Celyad Oncology slips 5% after suspending developmemt of CYAD-01 in early-stage THINK trial